Volume transmission of substance p in striatum induced by intraplantar formalin injection attenuates nociceptive responses via activation of the Neurokinin 1 receptor

Journal of Pharmacological Sciences

Volumn 121, Issue 4, 2013, Pages 257-271

  Nakamura, Yoki ^a   Izumi, Hiroki ^a   Shimizu, Takumi ^a   Hisaoka Nakashima, Kazue ^a   Morioka, Norimitsu ^a   Nakata, Yoshihiro ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Formalin; Neurokinin 1 receptor; Striatum; Substance P; Volume transmission

Indexed keywords

2 BENZHYDRYL 3 (2 METHOXYBENZYLAMINO) 1 AZABICYCLO[2.2.2]OCTANE; FORMALDEHYDE; MESSENGER RNA; NEUROKININ 1 RECEPTOR; PREPROTACHYKININ; PROTEIN C FOS; SUBSTANCE P;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CFOS GENE; CONTROLLED STUDY; CORPUS STRIATUM; FACILITATION; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INTERNALIZATION; MALE; MICRODIALYSIS; NEUROTRANSMISSION; NOCICEPTION; NONHUMAN; PROTEIN SECRETION; RAT; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

EID: 84877624999     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.12218FP     Document Type: Article

References (68)

1. Tepper JM, Abercrombie ED, Bolam JP. Basal ganglia macrocircuits. Prog Brain Res. 2007;160:3-7.
2. Durieux PF, Schiffmann SN, de Kerchove d'Exaerde A. Targeting neuronal populations of the striatum. Front Neuroanat. 2011;5:40.
3. Ke mp JM. Observations on the caudate nucleus of the cat impregnated with the Golgi method. Brain Res. 1968;11: 467-470.
4. Young WS, Bonner TI, Brann MR. Mesencephalic dopamine neurons regulate the expression of neuropeptide mRNAs in the rat forebrain. Proc Natl Acad Sci U S A. 1986;83:9827-9831.
5. Gerfen CR, Engber TM, Mahan LC, Susel Z, Chase TN, Monsma FJ, et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science. 1990; 250:1429-1432.
6. Aubry JM, Lundström K, Kawashima E, Ayala G, Schulz P, Bartanusz V, et al. NK1 receptor expression by cholinergic interneurones in human striatum. Neuroreport. 1994;5:1597- 1600.
7. Mao J, Mayer DJ, Price DD. Patterns of increased brain activity indicative of pain in a rat model of peripheral mononeuropathy. J Neurosci. 1993;13:2689-2702.
8. Shih YY, Chang C, Chen JC, Jaw FS. BOLD fMRI mapping of brain responses to nociceptive stimuli in rats under ketamine anesthesia. Med Eng Phys. 2008;30:953-958.
9. Yang PF, Chen DY, Hu JW, Chen JH, Yen CT. Functional tracing of medial nociceptive pathways using activity-dependent manganese-enhanced MRI. Pain. 2011;152:194-203.
10. Chudler EH, Sugiyama K, Dong WK. Nociceptive responses in the neostriatum and globus pallidus of the anesthetized rat. J Neurophysiol. 1993;69:1890-1903.
11. Chudler EH. Response properties of neurons in the caudateputamen and globus pallidus to noxious and non-noxious thermal stimulation in anesthetized rats. Brain Res. 1998;812:283-288.
12. Barceló AC, Filippini B, Pazo JH. The striatum and pain modula tion. Cell Mol Neurobiol. 2012;32:1-12.
13. Gear RW, Levine JD. Rostral ventral medulla cholinergic mechanism in pain-induced analgesia. Neurosci Lett. 2009;464: 170-172.
14. Magn usson JE, Fisher K. The involvement of dopamine in nociception: the role of D(1) and D(2) receptors in the dorsolateral striatum. Brain Res. 2000;855:260-266.
15. O'Connor T, O'Connell J, O'Brien D, Goode T, Bredin C, Shanahan F. The role of substance P in inflammatory disease. J Cell Physiol. 2004;201:167-180.
16. Kraft M, Noailles P, Angulo JA. Substance P modulates cocaine-evoked dopamine overflow in the striatum of the rat brain. Ann N Y Acad Sci. 2001;937:121-131.
17. Pompei P, Severini R, Costa G, Massi M, Fattoretti P, Bertoni- Freddari C. In situ hybridization analysis of preprotachykinin-A mRNA levels in young and old rats. Brain Res Mol Brain Res. 1999;64:132-136.
18. Severini C, Improta G, Falconieri-Erspamer G, Salvadori S, Erspamer V. The tachykinin peptide family. Pharmacol Rev. 2002;54:285-322.
19. Beiske AG, Loge JH, Rønningen A, Svensson E. Pain in Parkinson's disease: prevalence and characteristics. Pain. 2009; 141:173-177.
20. Boivie J. Pain in Parkinson's disease (PD). Pain. 2009;141:2-3.
21. Ford B. Parkinson disease: pain in Parkinson disease: the hidden epidemic. Nat Rev Neurol. 2009;5:242-243.
22. Letro GH, Quagliato EM, Viana MA. Pain in Parkinson's disease. Arq Neuropsiquiatr. 2009;67:591-594.
23. Fernandez A, de Ceballos ML, Jenner P, Marsden CD. Striatal neuropeptide levels in Parkinson's disease patients. Neurosci Lett. 1992;145:171-174.
24. Pezzoli G, Panerai AE, Di Giulio A, Longo A, Passerini D, Carenzi A. Methionine-enkephalin, substance P, and homovanillic acid in the CSF of parkinsonian patients. Neurology. 1984;34:516-519.
25. Ebner K, Rupniak NM, Saria A, Singewald N. Substance P in the medial amygdala: emotional stress-sensitive release and modulation of anxiety-related behavior in rats. Proc Natl Acad Sci U S A. 2004;101:4280-4285.
26. Singe wald N, Chicchi GG, Thurner CC, Tsao KL, Spetea M, Schmidhammer H, et al. Modulation of basal and stress-induced amygdaloid substance P release by the potent and selective NK1 receptor antagonist L-822429. J Neurochem. 2008;106: 2476-2488.
27. Deyama S, Yamamoto J, Machida T, Tanimoto S, Nakagawa T, Kaneko S, et al. Inhibition of glutamatergic transmission by morphine in the basolateral amygdaloid nucleus reduces paininduced aversion. Neurosci Res. 2007;59:199-204.
28. Gygi SP, Gibb JW, Johnson M, Hanson GR. Blockade of tachykinin NK1 receptors by CP-96345 enhances dopamine release and the striatal dopamine effects of methamphetamine in rats. Eur J Pharmacol. 1993;250:177-180.
29. Ji G, Neugebauer V. Pro- and anti-nociceptive effects of corticotropin-releasing factor (CRF) in central amygdala neurons are mediated through different receptors. J Neurophysiol. 2008; 99:1201-1212.
30. Fuxe K, Dahlström A, Höistad M, Marcellino D, Jansson A, Rivera A, et al. From the Golgi-Cajal mapping to the transmitterbased characterization of the neuronal networks leading to two modes of brain communication: wiring and volume transmission. Brain Res Rev. 2007;55:17-54.
31. Segawa T, Nakata Y, Yajima H, Kitagawa K. Further observation on the lack of active uptake system for substance P in the central nervous system. Jpn J Pharmacol. 1977;27:573-580.
32. Tjølsen A, Berge OG, Hunskaar S, Rosland JH, Hole K. The formalin test: an evaluation of the method. Pain. 1992;51:5-17.
33. Shibata M, Ohkubo T, Takahashi H, Inoki R. Modified formalin test: characteristic biphasic pain response. Pain. 1989;38:347-352.
34. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. Compact 3rd edition. Orlando: Academic Press; 1997.
35. Miyano K, Tang H, Nakamura Y, Morioka N, Inoue A, Nakata Y. Paclitaxel and vinorelbine, evoked the release of substance P from cultured rat dorsal root ganglion cells through different PKC isoform-sensitive ion channels. Neuropharmacology. 2009; 57:25-32.
36. Ptak K, Burnet H, Blanchi B, Sieweke M, De Felipe C, Hunt SP, et al. The murine neurokinin NK1 receptor gene contributes to the adult hypoxic facilitation of ventilation. Eur J Neurosci. 2002;16:2245-2252.
37. Vigna SR, Bowden JJ, McDonald DM, Fisher J, Okamoto A, McVey DC, et al. Characterization of antibodies to the rat substance P (NK-1) receptor and to a chimeric substance P receptor expressed in mammalian cells. J Neurosci. 1994;14: 834-845.
38. Liu H, Brown JL, Jasmin L, Maggio JE, Vigna SR, Mantyh PW, et al. Synaptic relationship between substance P and the substance P receptor: light and electron microscopic characterization of the mismatch between neuropeptides and their receptors. Proc Natl Acad Sci U S A. 1994;91:1009-1013.
39. Mantyh PW, DeMaster E, Malhotra A, Ghilardi JR, Rogers SD, Mantyh CR, et al. Receptor endocytosis and dendrite reshaping in spinal neurons after somatosensory stimulation. Science. 1995;268:1629-1632.
40. Morioka N, Sugimoto T, Tokuhara M, Dohi T, Nakata Y. Noradrenaline induces clock gene Per1 mRNA expression in C6 glioma cells through beta(2)-adrenergic receptor coupled with protein kinase A- cAMP response element binding protein (PKA-CREB) and Src-tyrosine kinase- glycogen synthase kinase-3beta (Src-GSK-3beta). J Pharmacol Sci. 2010;113: 234-245.
41. Han JS, Li W, Neugebauer V. Critical role of calcitonin generelated peptide 1 receptors in the amygdala in synaptic plasticity and pain behavior. J Neurosci. 2005;25:10717-10728.
42. Han JS, Neugebauer V. mGluR1 and mGluR5 antagonists in the amygdala inhibit different components of audible and ultrasonic vocalizations in a model of arthritic pain. Pain. 2005;113: 211-222.
43. Ji G, Neugebauer V. Differential effects of CRF1 and CRF2 receptor antagonists on pain-related sensitization of neurons in the central nucleus of the amygdala. J Neurophysiol. 2007;97: 3893-3904.
44. Li W, Neugebauer V. Block of NMDA and non-NMDA receptor activation results in reduced background and evoked activity of central amygdala neurons in a model of arthritic pain. Pain. 2004;110:112-122.
45. Li W, Neugebauer V. Differential changes of group II and group III mGluR function in central amygdala neurons in a model of arthritic pain. J Neurophysiol. 2006;96:1803-1815.
46. Chen CY, Bechtold AG, Tabor J, Bonham AC. Exercise reduces GABA synaptic input onto nucleus tractus solitarii baroreceptor second-order neurons via NK1 receptor internalization in spontaneously hypertensive rats. J Neurosci. 2009;29:2754-2761.
47. Zhang G, Chen W, Lao L, Marvizón JC. Cannabinoid CB1 receptor facilitation of substance P release in the rat spinal cord, measured as neurokinin 1 receptor internalization. Eur J Neurosci. 2010;31:225-237.
48. Huang PP, Khan I, Suhail MS, Malkmus S, Yaksh TL. Spinal botulinum neurotoxin B: effects on afferent transmitter release and nociceptive processing. PLoS One. 2011;6:e19126.
49. N akamura Y, Une Y, Miyano K, Abe H, Hisaoka K, Morioka N, et al. Activation of transient receptor potential Ankyrin 1 evokes nociception through substance P release from primary sensory neurons. J Neurochem. 2012; 120:1036-1047.
50. A mbriz-Tututi M, Sánchez-González V, Drucker-Colín R. Chromaffin cell transplant in spinal cord reduces secondary allodynia induced by formalin in the rat. Role of opioid receptors and α2-adrenoceptors. Eur J Pharmacol. 2011;668:147-154.
51. Bravo-Hernández M, Cervantes-Durán C, Pineda-Farias JB, Barragán-Iglesias P, López-Sánchez P, Granados-Soto V. Role of peripheral and spinal 5-HT(3) receptors in development and maintenance of formalin-induced long-term secondary allodynia and hyperalgesia. Pharmacol Biochem Behav. 2012;101: 246-257.
52. Boutelle M G, Zetterström T, Pei Q, Svensson L, Fillenz M. In vivo neurochemical effects of tail pinch. J Neurosci Methods. 1990;34:151-157.
53. Agnati LF, Fuxe K, Zoli M, Ozini I, Toffano G, Ferraguti F. A correlation analysis of the regional distribution of central enkephalin and beta-endorphin immunoreactive terminals and of opiate receptors in adult and old male rats. Evidence for the existence of two main types of communication in the central nervous system: the volume transmission and the wiring transmission. Acta Physiol Scand. 1986;128:201-207.
54. Almeida TF, Roizenblatt S, Tufik S. Afferent pain pathways: a neuroanatomical review. Brain Res. 2004;1000:40-56.
55. Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain. Cell. 2009;139:267-284.
56. Dickenson A H, Sullivan AF. Peripheral origins and central modulation of subcutaneous formalin-induced activity of rat dorsal horn neurones. Neurosci Lett. 1987;83:207-211.
57. Puig S, Sor kin LS. Formalin-evoked activity in identified primary afferent fibers: systemic lidocaine suppresses phase-2 activity. Pain. 1996;64:345-355.
58. Gerfen CR, Young WS. Distribution of striatonigral and striatopallidal peptidergic neurons in both patch and matrix compartments: an in situ hybridization histochemistry and fluorescent retrograde tracing study. Brain Res. 1988;460:161-167.
59. Basile AS, Janowsky A, Golembiowska K, Kowalska M, Tam E, Benveniste M, et al. Characterization of the antinociceptive actions of bicifadine in models of acute, persistent, and chronic pain. J Pharmacol Exp Ther. 2007;321:1208-1225.
60. Sin M, Mich elhaugh SK, Bannon MJ. D1 receptor regulation of preprotachykinin-A gene by extracellular signal-regulated kinase pathway in striatal cultures. Neuroreport. 2008;19: 187-191.
61. Miyano K, M orioka N, Sugimoto T, Shiraishi S, Uezono Y, Nakata Y. Activation of the neurokinin-1 receptor in rat spinal astrocytes induces Ca2+ release from IP3-sensitive Ca2+ stores and extracellular Ca2+ influx through TRPC3. Neurochem Int. 2010;57:923-934.
62. Stiller CO, Taylor BK, Linderoth B, Gustafsson H, Warsame Afrah A, Brodin E. Microdialysis in pain research. Adv Drug Deliv Rev. 2003;55:1065-1079.
63. Caioli S, C urcio L, Pieri M, Antonini A, Marolda R, Severini C, et al. Substance P receptor activation induces downregulation of the AMPA receptor functionality in cortical neurons from a genetic model of Amyotrophic Lateral Sclerosis. Neurobiol Dis. 2011;44:92-101.
64. Parenti C, Aricò G, Ronsisvalle G, Scoto GM. Supraspinal injection of Substance P attenuates allodynia and hyperalgesia in a rat model of inflammatory pain. Peptides. 2012;34:412-418.
65. Rosén A, Zhan g YX, Lund I, Lundeberg T, Yu LC. Substance P microinjected into the periaqueductal gray matter induces antinociception and is released following morphine administration. Brain Res. 2004;1001:87-94.
66. Anderson JJ, C hase TN, Engber TM. Substance P increases release of acetylcholine in the dorsal striatum of freely moving rats. Brain Res. 1993;623:189-194.
67. Govindaiah G, Wang Y, Cox CL. Substance P selectively modulates GABA(A) receptor-mediated synaptic transmission in striatal cholinergic interneurons. Neuropharmacology. 2010; 58:413-422.
68. Urban LA, Fox AJ. NK1 receptor antagonists- are they really without effect in the pain clinic? Trends Pharmacol Sci. 2000; 21:462-464.